Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study

Tania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, Dylan Trundell, Thomas Kustermann, Tanya Simuni, Kenneth Marek, Nicola Pavese, Klaus Seppi, Fabrizio Stocchi, Ronald B Postuma, Nathalie Pross, Annabelle Monnet, Gesine Respondek, Valerie Schlegel, Lauren Boak, Loes Rutten-Jacobs, Geoffrey A Kerchner, Patrik Brundin, Hanno Svoboda, Azad Bonni

Open source

DOI: 10.1016/s0140-6736(26)00865-2
Published: 2026-05
Container: The Lancet
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00865-2,
  title = {Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study},
  author = {Tania Nikolcheva and Gennaro Pagano and Judith Anzures-Cabrera and Dylan Trundell and Thomas Kustermann and Tanya Simuni and Kenneth Marek and Nicola Pavese and Klaus Seppi and Fabrizio Stocchi and Ronald B Postuma and Nathalie Pross and Annabelle Monnet and Gesine Respondek and Valerie Schlegel and Lauren Boak and Loes Rutten-Jacobs and Geoffrey A Kerchner and Patrik Brundin and Hanno Svoboda and Azad Bonni},
  year = {2026},
  journal = {The Lancet},
  doi = {10.1016/s0140-6736(26)00865-2},
  url = {https://doi.org/10.1016/s0140-6736(26)00865-2}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study
AU  - Tania Nikolcheva
AU  - Gennaro Pagano
AU  - Judith Anzures-Cabrera
AU  - Dylan Trundell
AU  - Thomas Kustermann
AU  - Tanya Simuni
AU  - Kenneth Marek
AU  - Nicola Pavese
AU  - Klaus Seppi
AU  - Fabrizio Stocchi
AU  - Ronald B Postuma
AU  - Nathalie Pross
AU  - Annabelle Monnet
AU  - Gesine Respondek
AU  - Valerie Schlegel
AU  - Lauren Boak
AU  - Loes Rutten-Jacobs
AU  - Geoffrey A Kerchner
AU  - Patrik Brundin
AU  - Hanno Svoboda
AU  - Azad Bonni
PY  - 2026
JO  - The Lancet
DO  - 10.1016/s0140-6736(26)00865-2
UR  - https://doi.org/10.1016/s0140-6736(26)00865-2
ER  -

APA

Nikolcheva, T., Pagano, G., Anzures-Cabrera, J., Trundell, D., Kustermann, T., Simuni, T., Marek, K., Pavese, N., Seppi, K., Stocchi, F., Postuma, R. B., Pross, N., Monnet, A., Respondek, G., Schlegel, V., Boak, L., Rutten-Jacobs, L., Kerchner, G. A., Brundin, P., Svoboda, H., & Bonni, A. (2026). Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study. The Lancet. https://doi.org/10.1016/s0140-6736(26)00865-2

Source records

crossref · retrieved 2026-09-26T18:49:39.281Z